HOME >> BIOLOGY >> NEWS
Epimmune scientists report positive pre-clinical data on vaccine designed to combat HIV's ability to mutate

who do not progress to AIDS for long periods even without anti-retroviral drug therapy. Epimmunes approach to vaccine development is based on epitopes from non-mutating regions of multiple virus proteins that are specifically selected for their ability to stimulate two types of cellular immunity, cytotoxic T-cells (CTLs) and helper T-cells (HTLs). Together, CTLs and HTLs comprise the bodys natural defense against HIV in which CTLs are capable of directly destroying virus-infected cells but require HTLs, which produce immune-boosting chemicals, for proper functioning.

Epimmune has designed its vaccine to provide immunity against many HIV clades (HIV strains that are common to a certain geographical region), including those that are prevalent in the United States, Europe, Africa and India. The vaccine is also designed to provide broad population coverage regardless of ethnicity.

Epimmunes vaccine will be delivered as DNA in combination with PVP, a polymer gene delivery technology licensed from Valentis, Inc. The PVP polymer has been shown to increase the efficiency of vaccine uptake by immune cells and enhance potency in animal studies. Epimmune has also linked its HIV vaccine with its proprietary PADRE universal helper T-cell epitope. PADRE is an HTL booster which, when combined with CTL epitopes, enhances the magnitude and duration of the immune response. Finally, the vaccine construct has also been optimized to ensure that the epitopes are processed efficiently and correctly once inside the cell. The epitopes are placed in a specific order (like beads on a string) that allows cellular enzymes to recognize the appropriate places to liberate the epitopes from the chain, thus improving the efficiency and potency of the vaccine.


'"/>

Contact: Laura Hansen
lhansen@irpr.com
858-860-0266
Epimmune, Inc.
1-Apr-2001


Page: 1 2

Related biology news :

1. DNA lends scientists a hand, revealing new chemical reactions
2. Conference at UH opens doors for new scientists, engineers
3. Wisconsin scientists develop quick botox test
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Alaska scientists find Arctic tundra yields surprising carbon loss
6. UAF scientists discover new marine habitat in Alaska
7. Information system to help scientists analyze mechanisms of social behavior
8. Zoonotic diseases - European scientists unite to fight diseases
9. Israeli scientists reveal the plan of a key cellular machine
10. Study by Israeli scientists provides insight on DNA code
11. Computer scientists at UH developing nurturing computers

Post Your Comments:
(Date:7/27/2014)... vitro study has revealed that nicotine and cotinine, a ... by a certain carcinogen in smoke. , The carcinogen ... tobacco leaves and ultimately ends up in the tobacco ... and liver, where it is activated by a variety ... mice has revealed that nicotine can partially interfere with ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
(Date:7/26/2014)... (PRWEB) July 26, 2014 Canada ... key market data on the Canada Endoscopy Visualization ... of US dollars, volume (in units) and average ... High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems ... Report at http://www.marketresearchreports.biz/analysis/213254 . , The report ...
(Date:7/25/2014)... 2014 "Ischemic Stroke and Cerebral ... data on the Ischemic Stroke and Cerebral Stroke ... and data relating to the clinical trials on ... global Ischemic Stroke Research Report 2014 at: ... the trial numbers and their recruitment status as ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... -- Trillions of bacteria live in each person,s digestive ... digest food and stave off harmful infections, but their ... To help shed light on the role of these ... professor Eric Alm recently tracked fluctuations in the bacterial ... The findings, described in the July 25 issue of ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
Cached News: